A nurse assesses a client's respiratory rate at 8/min after opioid administration. What is the priority action?

Menorrhagia involves excessive uterine bleeding that can lead to significant iron-deficiency anemia and hemodynamic instability. The depletion of total body iron stores occurs when blood loss exceeds the marrow's regenerative capacity, resulting in microcytic, hypochromic erythrocytes. This reduces the oxygen-carrying capacity of the blood.

A. Pain: While heavy bleeding can be associated with dysmenorrhea or uterine fibroids, pain is subjective and typically not life-threatening. Anemia poses a greater physiological risk to the client's systemic stability and cardiac output. Pain management is secondary to hemodynamic restoration in acute hemorrhage.

B. Anemia: Chronic or acute blood loss triggers a drop in hemoglobin and hematocrit levels, leading to fatigue, dyspnea, and tachycardia. Severe anemia can necessitate blood transfusions or intravenous iron therapy to prevent tissue hypoxia. It is the most immediate systemic complication of heavy menses.

C. Infection: Menorrhagia itself is not a primary risk factor for infection unless it is associated with retained products of conception or pelvic inflammatory disease. While blood can act as a medium for pathogens, hematological depletion is a more direct and frequent consequence of the volume of loss.

D. Infertility: While conditions causing heavy bleeding, like endometriosis or polyps, may impact conception, infertility is a long-term concern rather than an acute physiological priority. The nurse must first address the hemodynamic consequences of the current bleeding episode before focusing on future reproductive goals.

Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the enzyme cyclooxygenase, which is responsible for the synthesis of prostaglandins. Primary dysmenorrhea is caused by an excess of prostaglandin F2-alpha, which triggers intense uterine contractions and ischemia. Reducing these levels effectively alleviates menstrual cramping and associated systemic symptoms.

A. Antidepressants: While SSRIs are used for the emotional symptoms of premenstrual dysphoric disorder, they are not the first-line treatment for the physical pain of dysmenorrhea. They do not inhibit the uterine prostaglandins that cause the primary cramping. They address neurological rather than myometrial targets.

B. Insulin: Insulin is used to manage diabetes mellitus and has no clinical role in the treatment of menstrual pain. It does not affect uterine contractility or prostaglandin levels. Administering it to a non-diabetic client would cause life-threatening hypoglycemia.

C. Antibiotics: These agents treat infections like pelvic inflammatory disease, which can cause secondary dysmenorrhea. However, they are not used for the symptomatic relief of standard menstrual cramps. Antibiotics do not have analgesic or anti-inflammatory properties for non-infectious pelvic pain.

D. NSAIDS: Drugs like ibuprofen and naproxen are the gold standard for treating dysmenorrhea because they target the biochemical cause of the pain. By lowering prostaglandin concentrations in the menstrual fluid, they reduce uterine hypercontractility. This provides significant relief for most patients.